Maytansine class antibody drug conjugates: Research advances / 国际药学研究杂志

ABSTRACT

Compared with the traditional anti-tumor therapy, the antibody-based therapeutic strategies have shown considerably higher targeting selectivity and lower side effects. Antibody drug conjugates (ADC), combining the advantage of the biological antibodies and small molecule toxins, is regarded as a new way for the future cancer therapy. Maytansines are one of the cytotoxins widely used in ADC and the postmarketing ADC ado-trastuzumab emtansine (Kadcyla, ATE) which use such toxins successfully has expanded the indications from leukemia to other solid tumors. Currently, the clinical research progress in such ADC goes smoothly. This paper reviews the characteristics, metabolic characteristics, preparation of each component and the latest clinical research progress in the maytansine class ADC.